Observational studyMedicine2025
Association between the estimated plasma volume status and chronic kidney disease: A cross-sectional study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The ongoing discourse examines the connection between chronic kidney disease (CKD) and the estimated status of plasma volume (ePVS). In this context, we aimed to assess how effectively ePVS can influence both the prevalence of CKD and the risk of mortality, including from cardiovascular disease (CVD), in CKD patients. This study utilized data from 25,142 eligible participants in the NHANES 1999 to 2018 cohort. We employed binary logistic regression, Cox proportional hazards models, restricted cubic splines (RCS), and threshold analyses to investigate the association between ePVS and CKD. Additionally, we examined the relationship between ePVS and mortality outcomes, including all-cause and cardiovascular mortality. Of the 25,142 study participants, the weighted prevalence of CKD was 18.04%. A nonlinear correlation was observed between ePVS and CKD prevalence. Furthermore, a positive correlation was identified between ePVS and CKD risk, with ePVS values exceeding the threshold of 3.198 associated with an increased risk of CKD development. Therefore, ROC curves indicated that ePVS demonstrated modest discrimination in forecasting CKD. Overall, the relationship between ePVS and both CKD occurrence and all-cause, CVD mortality among patients with CKD was found to be stable across the majority of analyzed subgroups (P for interactions > .05). ePVS levels increased with the prevalence of CKD. Furthermore, early detection and intervention for elevated ePVS levels in CKD patients may influence the progression of CKD and improve their prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.